2024 Q1 Form 10-K Financial Statement
#000106299324006905 Filed on March 21, 2024
Income Statement
| Concept | 2024 Q1 | 2023 Q4 | 2023 |
|---|---|---|---|
| Revenue | $174.0K | $426.0K | $1.039M |
| YoY Change | 7.41% | 146.24% | 9.37% |
| Cost Of Revenue | $484.0K | $541.0K | $1.733M |
| YoY Change | 2.54% | 13.42% | -6.73% |
| Gross Profit | -$310.0K | -$115.0K | -$694.0K |
| YoY Change | 0.0% | -62.17% | -23.57% |
| Gross Profit Margin | -178.16% | -27.0% | -66.79% |
| Selling, General & Admin | $1.934M | $906.0K | $4.757M |
| YoY Change | 49.34% | -29.88% | 1.28% |
| % of Gross Profit | |||
| Research & Development | $789.0K | $771.0K | $3.274M |
| YoY Change | -4.01% | 3.91% | 8.02% |
| % of Gross Profit | |||
| Depreciation & Amortization | $202.0K | $176.0K | $766.0K |
| YoY Change | 5.21% | -7.37% | -1.42% |
| % of Gross Profit | |||
| Operating Expenses | $3.409M | $1.856M | $10.53M |
| YoY Change | 22.58% | -16.55% | 1.61% |
| Operating Profit | -$3.235M | -$1.971M | -$9.491M |
| YoY Change | 23.52% | -22.03% | 0.83% |
| Interest Expense | $792.0K | -$557.0K | $1.625M |
| YoY Change | 148.28% | 157.87% | 26.85% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$792.0K | -$436.0K | |
| YoY Change | 159.67% | -65.86% | |
| Pretax Income | -$4.027M | -$1.380M | -$9.927M |
| YoY Change | 37.72% | -49.71% | -7.14% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$4.027M | -$1.380M | -$9.927M |
| YoY Change | 37.72% | -49.71% | -7.14% |
| Net Earnings / Revenue | -2314.37% | -323.94% | -955.44% |
| Basic Earnings Per Share | -$0.02 | -$0.06 | |
| Diluted Earnings Per Share | -$0.02 | -$0.01 | -$0.06 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 174.7M shares | 174.7M shares | 174.7M shares |
| Diluted Shares Outstanding | 174.7M shares | 174.7M shares |
Balance Sheet
| Concept | 2024 Q1 | 2023 Q4 | 2023 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $772.0K | $2.282M | $2.282M |
| YoY Change | -79.9% | -9.7% | -9.7% |
| Cash & Equivalents | $772.0K | $2.282M | |
| Short-Term Investments | $0.00 | $0.00 | |
| Other Short-Term Assets | $313.0K | $298.0K | $298.0K |
| YoY Change | -22.91% | -9.97% | -9.97% |
| Inventory | $173.0K | $71.00K | $71.00K |
| Prepaid Expenses | $239.0K | $223.0K | |
| Receivables | $618.0K | $622.0K | $622.0K |
| Other Receivables | $201.0K | $168.0K | $168.0K |
| Total Short-Term Assets | $2.077M | $3.441M | $3.441M |
| YoY Change | -59.29% | -9.16% | -9.16% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $3.682M | $3.958M | $4.591M |
| YoY Change | -14.73% | -10.55% | -10.98% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $244.0K | $250.0K | $250.0K |
| YoY Change | -0.41% | 2.04% | 2.04% |
| Total Long-Term Assets | $4.471M | $4.841M | $4.841M |
| YoY Change | -14.66% | -10.39% | -10.39% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $2.077M | $3.441M | $3.441M |
| Total Long-Term Assets | $4.471M | $4.841M | $4.841M |
| Total Assets | $6.548M | $8.282M | $8.282M |
| YoY Change | -36.68% | -9.88% | -9.88% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $3.023M | $2.661M | $2.661M |
| YoY Change | 20.25% | 26.59% | 26.59% |
| Accrued Expenses | $1.668M | $1.249M | $1.497M |
| YoY Change | 600.84% | 429.24% | 534.32% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $10.73M | $3.057M | $3.057M |
| YoY Change | |||
| Long-Term Debt Due | $82.00K | $90.00K | $90.00K |
| YoY Change | -99.04% | 150.0% | |
| Total Short-Term Liabilities | $16.52M | $8.423M | $8.423M |
| YoY Change | 46.3% | 254.8% | 254.8% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $5.228M | $11.88M | $11.88M |
| YoY Change | 115.93% | 21.01% | |
| Other Long-Term Liabilities | $170.0K | $230.0K | $230.0K |
| YoY Change | -54.67% | -45.88% | -45.88% |
| Total Long-Term Liabilities | $5.398M | $12.11M | $12.11M |
| YoY Change | 120.11% | 18.23% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $16.52M | $8.423M | $8.423M |
| Total Long-Term Liabilities | $5.398M | $12.11M | $12.11M |
| Total Liabilities | $21.91M | $20.53M | $20.53M |
| YoY Change | 31.58% | 62.76% | 62.76% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$82.48M | -$78.46M | |
| YoY Change | 15.44% | 14.49% | |
| Common Stock | $1.000K | $1.000K | |
| YoY Change | 0.0% | 0.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$15.37M | -$12.25M | -$12.25M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $6.548M | $8.282M | $8.282M |
| YoY Change | -36.68% | -9.88% | -9.88% |
Cashflow Statement
| Concept | 2024 Q1 | 2023 Q4 | 2023 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$4.027M | -$1.380M | -$9.927M |
| YoY Change | 37.72% | -49.71% | -7.14% |
| Depreciation, Depletion And Amortization | $202.0K | $176.0K | $766.0K |
| YoY Change | 5.21% | -7.37% | -1.42% |
| Cash From Operating Activities | -$2.856M | -$525.0K | -$6.525M |
| YoY Change | 26.26% | -79.44% | -31.43% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $60.00K | $180.0K |
| YoY Change | -100.0% | 150.0% | -33.58% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $174.0K | $1.354M | |
| YoY Change | -92.43% | -64.18% | |
| Cash From Investing Activities | $0.00 | $114.0K | $1.174M |
| YoY Change | -100.0% | -94.99% | -66.54% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $943.0K | 1.166M | $6.776M |
| YoY Change | -74.15% | -11760.0% | 128.53% |
| NET CHANGE | |||
| Cash From Operating Activities | -$2.856M | -525.0K | -$6.525M |
| Cash From Investing Activities | $0.00 | 114.0K | $1.174M |
| Cash From Financing Activities | $943.0K | 1.166M | $6.776M |
| Net Change In Cash | -$1.913M | 755.0K | $1.425M |
| YoY Change | -245.81% | -363.07% | -146.84% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$2.856M | -$525.0K | -$6.525M |
| Capital Expenditures | $0.00 | $60.00K | $180.0K |
| Free Cash Flow | -$2.856M | -$585.0K | -$6.705M |
| YoY Change | 22.26% | -77.3% | -31.49% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023 | dei |
Document Type
DocumentType
|
10-K | |
| CY2023 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
| CY2023 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2023 | dei |
Entity File Number
EntityFileNumber
|
000-31187 | |
| CY2023 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
| CY2023 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
87-0638336 | |
| CY2023 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
6420 Abrams, Ville Saint Laurent | |
| CY2023 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Quebec | |
| CY2023 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
H4S 1Y2 | |
| CY2023 | dei |
City Area Code
CityAreaCode
|
514 | |
| CY2023 | dei |
Local Phone Number
LocalPhoneNumber
|
331-7440 | |
| CY2023 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.00001 par value | |
| CY2023 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2023 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
62000 | usd |
| CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
3441000 | usd |
| CY2023Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
250000 | usd |
| CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
20529000 | usd |
| CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
113000 | usd |
| CY2022 | us-gaap |
Investment Tax Credit
InvestmentTaxCredit
|
378000 | usd |
| CY2023 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2023 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
248000 | usd |
| CY2023 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2023 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2023 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2023Q2 | dei |
Entity Public Float
EntityPublicFloat
|
23983889 | usd |
| CY2023 | dei |
Auditor Location
AuditorLocation
|
Montreal, Quebec | |
| CY2023 | dei |
Auditor Name
AuditorName
|
Richter LLP | |
| CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
137000 | usd |
| CY2023Q4 | us-gaap |
Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
|
168000 | usd |
| CY2022Q4 | us-gaap |
Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
|
159000 | usd |
| CY2023Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
75000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
71000 | usd |
| CY2022Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
245000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
633000 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
732000 | usd |
| CY2023Q4 | us-gaap |
Assets
Assets
|
8282000 | usd |
| CY2022Q4 | us-gaap |
Assets
Assets
|
9190000 | usd |
| CY2023Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
2661000 | usd |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
580000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
174658096 | shares |
| CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
174646196 | shares |
| CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | usd |
| CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | usd |
| CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
68662000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-12247000 | usd |
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
67340000 | usd |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-78457000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3423000 | usd |
| CY2023 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-219000 | usd |
| CY2023 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
1148000 | usd |
| CY2023 | igxt |
Warrants Transaction Cost
WarrantsTransactionCost
|
89000 | usd |
| CY2023 | igxt |
Adjustments To Additional Paid In Capital Warrant Issued Two
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedTwo
|
912000 | usd |
| CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9927000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-12247000 | usd |
| CY2023 | igxt |
Lease Expense
LeaseExpense
|
-1000 | usd |
| CY2022 | igxt |
Lease Expense
LeaseExpense
|
2000 | usd |
| CY2022 | igxt |
Total Adjustments
TotalAdjustments
|
-9462000 | usd |
| CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
|
48000 | usd |
| CY2022 | igxt |
Stock Issued During Period Interest Paid Value
StockIssuedDuringPeriodInterestPaidValue
|
171000 | usd |
| CY2022 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
113000 | usd |
| CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10690000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3423000 | usd |
| CY2023 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
41000 | usd |
| CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-9927000 | usd |
| CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-10690000 | usd |
| CY2023 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | usd |
| CY2022 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-0 | usd |
| CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9927000 | usd |
| CY2023 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-219000 | usd |
| CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-863000 | usd |
| CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9927000 | usd |
| CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10690000 | usd |
| CY2023 | us-gaap |
Depreciation
Depreciation
|
766000 | usd |
| CY2022 | us-gaap |
Depreciation
Depreciation
|
777000 | usd |
| CY2022 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | usd |
| CY2022 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
-869000 | usd |
| CY2023 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-256000 | usd |
| CY2022 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
29000 | usd |
| CY2023 | us-gaap |
Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
|
-2995000 | usd |
| CY2023 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9491000 | usd |
| CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9413000 | usd |
| CY2023 | us-gaap |
Interest Expense
InterestExpense
|
1625000 | usd |
| CY2022 | us-gaap |
Interest Expense
InterestExpense
|
1281000 | usd |
| CY2022 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
6000 | usd |
| CY2023 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10146000 | usd |
| CY2022 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-11553000 | usd |
| CY2023 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
389000 | usd |
| CY2023 | us-gaap |
Accretion Expense
AccretionExpense
|
373000 | usd |
| CY2022 | us-gaap |
Accretion Expense
AccretionExpense
|
271000 | usd |
| CY2023 | igxt |
Interest Payable By Issuance Of Common Shares
InterestPayableByIssuanceOfCommonShares
|
0 | usd |
| CY2022 | igxt |
Interest Payable By Issuance Of Common Shares
InterestPayableByIssuanceOfCommonShares
|
171000 | usd |
| CY2023 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-87000 | usd |
| CY2022 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
32000 | usd |
| CY2023 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
9000 | usd |
| CY2022 | us-gaap |
Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
|
54000 | usd |
| CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6525000 | usd |
| CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9516000 | usd |
| CY2023 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
1118000 | usd |
| CY2023 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
3000000 | usd |
| CY2022 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
3000000 | usd |
| CY2023 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
58000 | usd |
| CY2022 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
35000 | usd |
| CY2022 | igxt |
Payments For Repurchase Of Convertible Notes
PaymentsForRepurchaseOfConvertibleNotes
|
0 | usd |
| CY2023 | us-gaap |
Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
|
37000 | usd |
| CY2022 | us-gaap |
Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
|
0 | usd |
| CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2965000 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9760448 | shares |
| CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y8M23D | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.3 | |
| CY2022 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-189000 | usd |
| CY2023 | igxt |
Proceeds From Issuance Convertible Notes
ProceedsFromIssuanceConvertibleNotes
|
697000 | usd |
| CY2023 | igxt |
Payments For Repurchase Of Convertible Notes
PaymentsForRepurchaseOfConvertibleNotes
|
40000 | usd |
| CY2023 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
6776000 | usd |
| CY2023 | us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
1354000 | usd |
| CY2023 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
1174000 | usd |
| CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
3509000 | usd |
| CY2023 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
1425000 | usd |
| CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-3042000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1210000 | usd |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
3945000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2282000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
1210000 | usd |
| CY2023 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
180000 | usd |
| CY2022 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
5739000 | usd |
| CY2022 | us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
9519000 | usd |
| CY2022 | igxt |
Manufacturing Costs In Inventory Amount Incurred
ManufacturingCostsInInventoryAmountIncurred
|
19000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
478000 | usd |
| CY2023Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
71000 | usd |
| CY2022Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
62000 | usd |
| CY2022 | igxt |
Research And Development Cost In Inventory Amount Incurred
ResearchAndDevelopmentCostInInventoryAmountIncurred
|
0 | usd |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5979000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3958000 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4425000 | usd |
| CY2023Q4 | igxt |
Commercial Sales Milestone Payments
CommercialSalesMilestonePayments
|
401000 | usd |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
174658096 | shares |
| CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
174646196 | shares |
| CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | usd |
| CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | usd |
| CY2023 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
389000 | usd |
| CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
113000 | usd |
| CY2023Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
472000 | usd |
| CY2022Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
39000 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2012000 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
5334198 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
0.4 | |
| CY2023Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
1012000 | usd |
| CY2023 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Depreciation And Amortization
IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization
|
203000 | usd |
| CY2022 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Depreciation And Amortization
IncomeTaxReconciliationNondeductibleExpenseDepreciationAndAmortization
|
-52000 | usd |
| CY2023 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
242000 | usd |
| CY2022Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
39000 | usd |
| CY2022 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
918000 | usd |
| CY2023 | us-gaap |
Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
|
41000 | usd |
| CY2022 | us-gaap |
Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
|
44000 | usd |
| CY2023Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
472000 | usd |
| CY2022Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
40452190 | shares |
| CY2022Q4 | igxt |
Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
|
0.2 | |
| CY2023 | igxt |
Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
|
16356850 | shares |
| CY2023 | igxt |
Class Of Warrant Or Right Granted In Period Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedInPeriodWeightedAverageExercisePrice
|
0.26 | |
| CY2023 | igxt |
Class Of Warrant Or Right Expirations In Period
ClassOfWarrantOrRightExpirationsInPeriod
|
17459190 | shares |
| CY2023 | igxt |
Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice
|
0.57 | |
| CY2023 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-2623000 | usd |
| CY2022 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-3062000 | usd |
| CY2022 | igxt |
Net Operating Losses For Which No Tax Benefits Have Been Recorded
NetOperatingLossesForWhichNoTaxBenefitsHaveBeenRecorded
|
1785000 | usd |
| CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
4376000 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
4122000 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
2780000 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
19875000 | usd |
| CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
22832000 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
19875000 | usd |
| CY2023 | us-gaap |
Revenues
Revenues
|
1039000 | usd |
| CY2022 | us-gaap |
Revenues
Revenues
|
950000 | usd |
| CY2023 | us-gaap |
Revenues
Revenues
|
1039000 | usd |
| CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
15259000 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
12789000 | usd |
| CY2023Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | usd |
| CY2023Q4 | igxt |
Non Refundable Tax Credits
NonRefundableTaxCredits
|
3391000 | usd |
| CY2022 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
269000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y2M12D | |
| CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.10 | pure |
| CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
273000 | usd |
| CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
273000 | usd |
| CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
592000 | usd |
| CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
114000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
248000 | usd |
| CY2023 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
58000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y4M24D | |
| CY2023Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0387 | pure |
| CY2023Q4 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
93000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
37000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
37000 | usd |
| CY2022Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
42000 | usd |
| CY2023 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001098880 | |
| CY2023 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2023 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2023 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
| CY2023Q4 | us-gaap |
Cash
Cash
|
2282000 | usd |
| CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1523000 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
236000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
90000 | usd |
| CY2022Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
36000 | usd |
| CY2023Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1118000 | usd |
| CY2022Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
0 | usd |
| CY2023Q4 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
2557000 | usd |
| CY2022Q4 | us-gaap |
Convertible Debt Current
ConvertibleDebtCurrent
|
0 | usd |
| CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
8423000 | usd |
| CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2374000 | usd |
| CY2023Q4 | us-gaap |
Loans Payable
LoansPayable
|
7401000 | usd |
| CY2022Q4 | us-gaap |
Loans Payable
LoansPayable
|
5500000 | usd |
| CY2023Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
4438000 | usd |
| CY2022Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
4272000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
230000 | usd |
| CY2023 | igxt |
Research And Development Cost In Inventory Amount Incurred
ResearchAndDevelopmentCostInInventoryAmountIncurred
|
10000 | usd |
| CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
580000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
174658096 | shares |
| CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
174646196 | shares |
| CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-68530000 | usd |
| CY2023Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2453000 | usd |
| CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2234000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-3423000 | usd |
| CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
8282000 | usd |
| CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9190000 | usd |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3871000 | usd |
| CY2022 | us-gaap |
Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
|
-302000 | usd |
| CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-863000 | usd |
| CY2022 | igxt |
Stock Issued During Period Repayment For Convertible Of Debentures
StockIssuedDuringPeriodRepaymentForConvertibleOfDebentures
|
4229000 | usd |
| CY2023 | igxt |
Agents Warrants
AgentsWarrants
|
19000 | usd |
| CY2023 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
389000 | usd |
| CY2023 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
1039000 | usd |
| CY2022 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
950000 | usd |
| CY2023 | us-gaap |
Revenues
Revenues
|
1039000 | usd |
| CY2022 | us-gaap |
Revenues
Revenues
|
950000 | usd |
| CY2023 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3274000 | usd |
| CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3031000 | usd |
| CY2023 | us-gaap |
Manufacturing Costs
ManufacturingCosts
|
1733000 | usd |
| CY2022 | us-gaap |
Manufacturing Costs
ManufacturingCosts
|
1858000 | usd |
| CY2023 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
4757000 | usd |
| CY2022 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
4697000 | usd |
| CY2023 | us-gaap |
Depreciation
Depreciation
|
766000 | usd |
| CY2022 | us-gaap |
Depreciation
Depreciation
|
777000 | usd |
| CY2023 | us-gaap |
Operating Expenses
OperatingExpenses
|
10530000 | usd |
| CY2022 | us-gaap |
Operating Expenses
OperatingExpenses
|
10363000 | usd |
| CY2022 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
4000 | usd |
| CY2022 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1277000 | usd |
| CY2023 | us-gaap |
Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
|
37000 | usd |
| CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
174654565 | shares |
| CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
164746054 | shares |
| CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
164746054 | shares |
| CY2023 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.06 | |
| CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.06 | |
| CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.07 | |
| CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.07 | |
| CY2023 | igxt |
Dsu Expenses
DsuExpenses
|
28000 | usd |
| CY2022 | igxt |
Dsu Expenses
DsuExpenses
|
-106000 | usd |
| CY2023 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
86000 | usd |
| CY2022 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
-277000 | usd |
| CY2023 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
9000 | usd |
| CY2022 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
0 | usd |
| CY2023 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
120000 | usd |
| CY2022 | us-gaap |
Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
|
-9000 | usd |
| CY2023 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1104000 | usd |
| CY2022 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-495000 | usd |
| CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
271000 | usd |
| CY2023 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-353000 | usd |
| CY2022 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
307000 | usd |
| CY2023 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="text-align: justify; margin-left: 18pt; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Use of Estimates</b></span></span></p> <p style="margin-left: 18pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, and the investment tax credits receivable. Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.</span></span></p> </div> | |
| CY2023 | us-gaap |
Investment Tax Credit
InvestmentTaxCredit
|
149000 | usd |
| CY2023 | igxt |
Manufacturing Costs In Inventory Amount Incurred
ManufacturingCostsInInventoryAmountIncurred
|
23000 | usd |
| CY2023Q4 | igxt |
Sales Tax Assessments Amount
SalesTaxAssessmentsAmount
|
322000 | usd |
| CY2023Q4 | igxt |
Interest And Penalties In Sales Tax Assessments
InterestAndPenaltiesInSalesTaxAssessments
|
35000 | usd |
| CY2023 | igxt |
Loss Contingency Increase In Sales Taxes Expenses
LossContingencyIncreaseInSalesTaxesExpenses
|
287000 | usd |
| CY2023 | igxt |
Loss Contingency Decrease In Net Earnings
LossContingencyDecreaseInNetEarnings
|
287000 | usd |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
580000000 | shares |
| CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
20000000 | shares |
| CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.00001 | |
| CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.00001 | |
| CY2023Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
472000 | usd |
| CY2021Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
41156990 | shares |
| CY2021Q4 | igxt |
Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
|
0.2 | |
| CY2022 | igxt |
Class Of Warrant Or Right Expirations In Period
ClassOfWarrantOrRightExpirationsInPeriod
|
704800 | shares |
| CY2022 | igxt |
Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice
|
0.18 | |
| CY2023 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
525000 | usd |
| CY2022 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
|
455000 | usd |
| CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
3388000 | usd |
| CY2023Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
22832000 | usd |
| CY2022Q4 | igxt |
Non Refundable Tax Credits
NonRefundableTaxCredits
|
3004000 | usd |
| CY2022 | us-gaap |
Revenues
Revenues
|
950000 | usd |
| CY2023 | us-gaap |
Revenues
Revenues
|
1039000 | usd |
| CY2022 | us-gaap |
Revenues
Revenues
|
950000 | usd |
| CY2023Q4 | igxt |
Research And Development Milestone Payments
ResearchAndDevelopmentMilestonePayments
|
2414000 | usd |
| CY2023 | igxt |
Percentages Of Recognized In Next Three Year
PercentagesOfRecognizedInNextThreeYear
|
1 | pure |
| CY2023 | us-gaap |
Interest Paid Net
InterestPaidNet
|
447000 | usd |
| CY2022 | us-gaap |
Interest Paid Net
InterestPaidNet
|
396000 | usd |
| CY2023 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
260000 | usd |
| CY2022 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
35000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
130000 | usd |
| CY2023 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
| CY2023 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2023 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-12-31 | |
| CY2023 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2023 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
| CY2023 | dei |
Entity Registrant Name
EntityRegistrantName
|
IntelGenx Technologies Corp. | |
| CY2023 | dei |
Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
|
false | |
| CY2024Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
174658096 | shares |
| CY2023 | dei |
Auditor Firm
AuditorFirmId
|
989 | |
| CY2022Q4 | us-gaap |
Cash
Cash
|
1210000 | usd |
| CY2023Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
0 | usd |
| CY2022Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
1317000 | usd |
| CY2023Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
622000 | usd |
| CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
709000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
223000 | usd |
| CY2022Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
194000 | usd |
| CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
3788000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3958000 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4425000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1249000 | usd |
| CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
579000 | usd |
| CY2023Q4 | us-gaap |
Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
|
500000 | usd |
| CY2022Q4 | us-gaap |
Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
|
0 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
425000 | usd |
| CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
12613000 | usd |
| CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2023Q4 | igxt |
Subsequent Event
SubsequentEvent
|
usd | |
| CY2022Q4 | igxt |
Subsequent Event
SubsequentEvent
|
usd | |
| CY2023 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2000 | usd |
| CY2023 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
1148000 | usd |
| CY2022 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | usd |
| CY2023 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-436000 | usd |
| CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10690000 | usd |
| CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
174654565 | shares |
| CY2023 | igxt |
Total Adjustments
TotalAdjustments
|
-9520000 | usd |
| CY2023 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
670000 | usd |
| CY2022 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
423000 | usd |
| CY2023 | us-gaap |
Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
|
500000 | usd |
| CY2022 | us-gaap |
Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
|
0 | usd |
| CY2023 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
2970000 | usd |
| CY2022 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
0 | usd |
| CY2023 | us-gaap |
Payments For Repurchase Of Private Placement
PaymentsForRepurchaseOfPrivatePlacement
|
258000 | usd |
| CY2022 | us-gaap |
Payments For Repurchase Of Private Placement
PaymentsForRepurchaseOfPrivatePlacement
|
0 | usd |
| CY2023 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2000 | usd |
| CY2022 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | usd |
| CY2023 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
0 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
2282000 | usd |
| CY2023 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="margin-left: 18pt; text-indent: -18pt; text-align: justify; margin-top: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><span><b>3.</b><span style="width: 10.16pt; text-indent: 0pt; display: inline-block;"> </span><b>Nature of Business</b></span></span></span></p> <p style="margin-left: 18pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">IntelGenx was incorporated in the State of Delaware as Big Flash Corp. on July 27, 1999. On April 28, 2006 Big Flash Corp. completed, through the Canadian holding corporation, the acquisition of IntelGenx Corp., a company incorporated in Canada on June 15, 2003 and headquartered in Montreal, Quebec. IntelGenx Corp. has continued operations as our operating subsidiary.</span></span></p> <p style="margin-left: 18pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">IntelGenx Corp. is a drug delivery company focused on the contract development and manufacturing of novel oral thin film products for the pharmaceutical market. More recently, IntelGenx made the decision to enter the psychedelic market. As a full service contract development and manufacturing organization ("CDMO") IntelGenx is offering partners a comprehensive portfolio of pharmaceutical services, including pharmaceutical research and development, clinical monitoring, regulatory support, technology transfer, manufacturing scale-up, and commercial manufacturing. The Company's main product development efforts are based upon three delivery platform technologies: (1) VersaFilm™, an oral film technology, (2) the VetaFilm<sup>TM</sup> technology platform for veterinary applications and (3) DisinteQ™ a disintegrating oral film technology.</span></span></p> <p style="margin-left: 18pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's business strategy is to leverage its proprietary drug delivery technologies and develop pharmaceutical products with tangible benefits for patients, for partners and, once the product launches, retain the exclusive manufacturing rights. </span></span></p> <p style="margin-left: 18pt; text-align: justify;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company has undertaken a strategy under which it will work with pharmaceutical companies in order to apply its oral film technology to pharmaceutical products for which patent protection is nearing expiration, a strategy which is often referred to as "lifecycle management." Under §505(b)(2) of the Food, Drug, and Cosmetics Act (the "FDCA"), the FDA may grant market exclusivity for a term of up to three years following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage, dosage form, route of administration or a combination.</span></span></p> <p style="margin-left: 18pt; text-align: justify; margin-bottom: 0pt;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The Company's product portfolio includes a blend of generic and branded products based on its proprietary delivery technology ("generic" products are essentially copies of products that have already received FDA approval). Of the 11 projects currently in the Company's portfolio, 10 use the <i>VersaFilm™</i> technology and one uses the <i>VetaFilm™</i> technology.</span></span></p> </div> | |
| CY2018Q2 | us-gaap |
Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
|
320 | shares |
| CY2018Q2 | us-gaap |
Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
|
3200000 | usd |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
9937000 | usd |
| CY2018Q2 | igxt |
Interest Rate On Convertible Note
InterestRateOnConvertibleNote
|
0.06 | pure |
| CY2018Q2 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
0.8 | |
| CY2018Q2 | us-gaap |
Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
|
243275 | shares |
| CY2018Q2 | igxt |
Equity Issuance Amount Per Share
EquityIssuanceAmountPerShare
|
0.8 | |
| CY2023 | igxt |
Gross Proceeds Of Units
GrossProceedsOfUnits
|
3200000 | usd |
| CY2023 | igxt |
Transaction Costs Of Units
TransactionCostsOfUnits
|
328000 | usd |
| CY2023 | igxt |
Net Proceeds Of Units
NetProceedsOfUnits
|
2872000 | usd |
| CY2023 | us-gaap |
Financing Interest Expense
FinancingInterestExpense
|
671000 | usd |
| CY2022 | us-gaap |
Financing Interest Expense
FinancingInterestExpense
|
423000 | usd |
| CY2023Q4 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
1249000 | usd |
| CY2022Q4 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
579000 | usd |
| CY2023 | igxt |
Accretion On Loan Payable
AccretionOnLoanPayable
|
86000 | usd |
| CY2022 | igxt |
Accretion On Loan Payable
AccretionOnLoanPayable
|
0 | usd |
| CY2023Q4 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
8500000 | usd |
| CY2023 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
1148000 | usd |
| CY2023 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
37000 | usd |
| CY2023 | igxt |
Accretion On Loan Payable
AccretionOnLoanPayable
|
86000 | usd |
| CY2023Q4 | us-gaap |
Loans Payable
LoansPayable
|
7401000 | usd |
| CY2022Q4 | igxt |
Number Of Authorized Shares Of Capital Stock
NumberOfAuthorizedSharesOfCapitalStock
|
470000000 | shares |
| CY2023Q4 | igxt |
Number Of Authorized Shares Of Capital Stock
NumberOfAuthorizedSharesOfCapitalStock
|
600000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
580000000 | shares |
| CY2023 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
11900 | shares |
| CY2023 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
11900 | shares |
| CY2023 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
0 | usd |
| CY2023 | igxt |
Cash Consideration For Stock Options Exercised
CashConsiderationForStockOptionsExercised
|
2000 | usd |
| CY2023 | igxt |
Increase In Additional Paid In Capital Due To Stock Options Exercised
IncreaseInAdditionalPaidInCapitalDueToStockOptionsExercised
|
2000 | usd |
| CY2023Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
39349850 | shares |
| CY2023Q4 | igxt |
Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
|
0.31 | |
| CY2024 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
|
100000 | shares |
| CY2024 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
18000 | usd |
| CY2023 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
13000 | usd |
| CY2024 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P3Y | |
| CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
|
153846 | shares |
| CY2023 | igxt |
Net Operating Losses For Which No Tax Benefits Have Been Recorded
NetOperatingLossesForWhichNoTaxBenefitsHaveBeenRecorded
|
1694000 | usd |
| CY2023Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
-191000 | usd |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
184000 | usd |
| CY2023Q4 | igxt |
Transaction Price Allocated To Remaining Performance Obligation
TransactionPriceAllocatedToRemainingPerformanceObligation
|
3359000 | usd |
| CY2023 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
259000 | usd |
| CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
267000 | usd |
| CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
46000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
230000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
3000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
127000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
90000 | usd |
| CY2023Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
37000 | usd |
